Truist lowered the firm’s price target on Option Care Health (OPCH) to $30 from $40 and keeps a Buy rating on the shares. The company reported mixed Q1 results, marked by better adjusted EBITDA and margins, with strong acute growth, though chronic inflammatory census saw stronger than anticipated headwinds, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health price target lowered to $26 from $38 at Deutsche Bank
- Option Care Health: Execution Risks, CID Headwinds Prompt EBITDA Cut and Price Target Reduction to $23, Supporting Hold Rating
- Option Care Health Balances CID Hit With Stable Profits
- Option Care Health price target lowered to $32 from $38 at Citizens
- Option Care Health falls -29.7%